Adjunctive therapies such as SGLT-2 inhibitors and novel iron formulations also hold promise as complementary options, offering a broader therapeutic toolkit for anemia management in CKD and cancer populations. This evidence concerns the gene SLC5A2 and chronic kidney disease.